Screener
AnaptysBio, Inc. ANAB Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 33,991 | 41,180 |
| General and administrative | 26,202 | 14,130 |
| Total operating expenses | 60,193 | 55,310 |
| Loss from operations | (34,637) | (27,539) |
| Other income (expense), net: | ||
| Interest income | 2,653 | 4,413 |
| Non-cash interest expense for the sale of future royalties | (20,859) | (18,061) |
| Other (expense) income, net | (1) | 1,902 |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s operating income?
- AnaptysBio, Inc. (ANAB) reported operating income of -$34.64M in Q1 2026.
- How has AnaptysBio, Inc.'s operating income changed year-over-year?
- AnaptysBio, Inc.'s operating income decreased by 25.8% year-over-year, from -$27.54M to -$34.64M.
- What is the long-term trend for AnaptysBio, Inc.'s operating income?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s operating income has grown at a -4.2% compound annual growth rate (CAGR), from -$56.81M to $47.9M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about AnaptysBio, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude